Nedometinib

Nedometinib (NFX-179) is a specific MEK1 inhibitor with an IC50 of 135 nM. Nedometinib inhibits p-ERK, MAPK. Nedometinib exerts anticancer activity against squamous cell carcinoma. Nedometinib can be used for research in dermatosis, neurofibromatosis[1][2].

Product Specifications

CAS Number

[2252314-46-6]

Product Name Alternative

NFX-179

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

MEK; p38 MAPK; PERK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/nedometinib.html

Purity

98.25

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=C(NC2=CC=C(C=C2F)I)N(C)C3=C1C=CC=N3)NOCCO

Molecular Formula

C17H16FIN4O3

Molecular Weight

470.24

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Kincaid, et al. Preparation of pyrrolopyridine-aniline compounds for treatment of dermal disorders. World Intellectual Property Organization, WO2018213810 A1. 2018-11-22.|[2]Sarin KY, et al. Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma. Sci Transl Med. 2023 Oct 11;15 (717) :eade1844.